Jose Kennedy Amaral

Dr. Jose Kennedy Amaral

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in The American Journal of Medicine
Verified
Journal Article
Closed access
JAJose Kennedy Amaral
Jose Kennedy Amaral
JBJoshua B. Bilsborrow
Joshua B. Bilsborrow
RSRobert T. Schoen
Robert T. Schoen

22 March 2019 in Viruses
Verified
Journal Article
Open access
PDF file
JAJose Kennedy Amaral
Jose Kennedy Amaral
Peter TaylorPeter Taylor
Peter Taylor
MTMauro Martins Teixeira
Mauro Martins Teixeira
TMThomas E. “Tem” Morrison
Thomas E. “Tem” Morrison
RSRobert Schoen
Robert Schoen
Chikungunya fever (CHIKF) is an emerging viral infection that has spread widely, along with its Aedes vectors, throughout the tropics and beyond, causing explosive epidemics of acute illness and persistent disabling arthritis. The rheumatic symptoms associated with chikungunya virus (CHIKV) infection include polyarthralgia, polyarthritis, morning stiffness, joint edema, and erythema. Chronic CHIK arthritis (CCA) often causes severe pain and associated disability. The pathogenesis of CCA is not well understood. Proposed hypotheses include the persistence of a low level of replicating virus in the joints, the persistence of viral RNA in the synovium, and the induction of autoimmunity. In this review, we describe the main hypotheses of CCA pathogenesis, some of which support methotrexate (MTX) treatment which has been shown to be effective in preliminary studies in CCA.

19 December 2022 in Travel Medicine and Infectious Disease
Verified
Journal Article
Open access
JAJose Kennedy Amaral
Jose Kennedy Amaral
CBClifton O. Bingham
Clifton O. Bingham
Peter TaylorPeter Taylor
Peter Taylor
LVLuis M. Vilá
Luis M. Vilá
MWMichael E. Weinblatt
Michael E. Weinblatt
RSRobert Schoen
Robert Schoen
Chikungunya virus (CHIKV) infection results from transmission by the mosquito vector. Following an incubation period of 5-7 days, patients develop an acute febrile illness, chikungunya fever (CHIKF), characterized by high fevers, maculopapular rash, headaches, polyarthritis/arthralgias, myalgias, nausea, vomiting, and diarrhea. Joint pain is often severe, and most often involves the hands, the wrists, the ankles, and the metatarsal-phalangeal joints of the feet. Many patients recover within several weeks, but up to 50% develop chronic joint pain and swelling for more than 12 weeks, then we refer to these symptoms as chronic chikungunya arthritis (CCA). The pathogenesis of CCA is not well understood. In this article, we suggest that mesenchymal stem cells (MSCs) may play an important role in this pathogenesis. This heterogeneous group of multipotent cells, morphologically similar to fibroblasts, may undergo epigenetic changes capable of generating aberrant progenies. However, we believe that there is no need for a latent infection. In our pathogenic hypothesis, CHIKV infection of MSCs would cause epigenetic changes both in MSCs themselves and in their progenies, without the need for reactivation of dormant viruses.

1 January 2023 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
JOJobson Lopes de Oliveira
Jobson Lopes de Oliveira
INIgor Albuquerque Nogueira
Igor Albuquerque Nogueira
JAJose Kennedy Amaral
Jose Kennedy Amaral
LCLuciana Ribeiro Campos
Luciana Ribeiro Campos
MMMariana Macêdo Militão Mendonça
Mariana Macêdo Militão Mendonça
RSRobert Schoen
Robert Schoen
Chikungunya fever (CHIK) is a neglected tropical disease associated with chronic arthritis. CHIK is usually a self-limiting condition; however, extra-articular manifestations present as atypical illness in a minority of patients. These atypical features may mimic other conditions and potentially distract physicians from the true diagnosis. This review analyzes the evidence of many unusual extra-articular manifestations reported in cases of CHIK. Depending on the affected system, these unusual manifestations include encephalitis, myocarditis, acute interstitial nephritis, cutaneous manifestations, acute anterior uveitis, abdominal pain, and depression. In addition, coinfections and comorbidities may cause atypical illness and obscure the diagnosis. Further studies are required to clarify the pathophysiology and natural history of CHIK, as it remains a burdening condition. Exploring its atypical symptoms may be the missing scientific piece of this puzzle.

1 January 2024 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
JAJose Kennedy Amaral
Jose Kennedy Amaral
PTPeter Charles Taylor
Peter Charles Taylor
RSRobert Schoen
Robert Schoen
Chikungunya fever is an emerging global infection transmitted by Aedes mosquitoes that manifests as an acute febrile illness with joint pain and can lead to chronic arthritis. The mechanism underlying chronic joint damage remains unclear; however, chronic chikungunya arthritis shares similarities with rheumatoid arthritis. Disease-modifying antirheumatic drugs have revolutionized rheumatoid arthritis treatment by preventing joint damage. However, the role of these therapies in chronic chikungunya arthritis has not been determined. We conducted a systematic review to evaluate the burden of joint structural damage in chronic chikungunya arthritis to help to define the role of disease-modifying therapy in this disease.

6 September 2023 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
JAJose Kennedy Amaral
Jose Kennedy Amaral
CBClifton O. Bingham
Clifton O. Bingham
Peter TaylorPeter Taylor
Peter Taylor
LVLuis M. Vilá
Luis M. Vilá
MWMichael E. Weinblatt
Michael E. Weinblatt
RSRobert Schoen
Robert Schoen
: Chikungunya fever is a global vector-borne viral disease. Patients with acute chikungunya are usually treated symptomatically. The arthritic phase may be self-limiting. However, many patients develop extremely disabling arthritis that does not improve after months. The aim of this study was to describe the treatment of chikungunya arthritis (CHIKA) patients. A medical records review was conducted in 133 CHIKA patients seen at a rheumatology practice. Patients were diagnosed by clinical criteria and confirmed by the presence of anti-chikungunya IgM. Patients were treated with methotrexate (20 mg/week) and/or leflunomide (20 mg/day) and dexamethasone (0–4 mg/day) for 4 weeks. At baseline visit and 4 weeks after treatment, Disease Activity Score 28 (DAS28) and pain (using a visual analog scale) were ascertained. Five months after the end of treatment, patients were contacted to assess pain, tender joint count, and swollen joint count. The mean age of patients was 58.6 ± 13.7 years, and 119 (85%) were female. After 4 weeks of treatment, mean (SD) DAS28-erythrocyte sedimentation rate (6.0 [1.2] versus 2.7 [1.0], P < 0.001) and pain (81.8 [19.2] to 13.3 [22.9], P < 0.001) scores significantly decreased. A total of 123 patients were contacted 5 months after the end of treatment. Pain score, tender joint count, and swollen joint count significantly declined after 4 weeks of treatment, and the response was sustained for 5 months. In this group of patients with CHIKA, 4-week treatment induced a rapid clinical improvement that was maintained 5 months after the end of therapy; however, the contribution of treatment to these outcomes is uncertain.